-
Views
-
Cite
Cite
Michael R. Clarkson, Louise Giblin, Fionnuala P. O'Connell, Patrick O'Kelly, Joseph J. Walshe, Peter Conlon, Yvonne O'Meara, Anthony Dormon, Eileen Campbell, John Donohoe, Acute interstitial nephritis: clinical features and response to corticosteroid therapy, Nephrology Dialysis Transplantation, Volume 19, Issue 11, November 2004, Pages 2778–2783, https://doi.org/10.1093/ndt/gfh485
- Share Icon Share
Abstract
Background. Acute interstitial nephritis (AIN) is a recognized cause of reversible acute renal failure characterized by the presence of an interstitial inflammatory cell infiltrate.
Methods. In order to evaluate the clinical characteristics and management of this disorder, we performed a retrospective study of all cases of AIN found by reviewing 2598 native renal biopsies received at our institution over a 12 year period. Presenting clinical, laboratory and histological features were identified, as was clinical outcome with specific regard to corticosteroid therapy response.
Results. AIN was found in 2.6% of native biopsies, and 10.3% of all biopsies performed in the setting of acute renal failure during the period analysed (n = 60). The incidence of AIN increased progressively over the period observed from 1 to 4% per annum. AIN was drug related in 92% of cases and appeared to be idiopathic in the remainder. The presenting symptoms included oliguria (51%), arthralgia (45%), fever (30%), rash (21%) and loin pain (21%). Median serum creatinine at presentation was 670 µmol/l [interquartile range (IQR) 431–1031] and 58% of cases required acute renal replacement therapy. Corticosteroid therapy was administered in 60% of cases. Serum creatinine at baseline was similar in the corticosteroid-treated and conservatively managed groups; 700 µmol/l (IQR 449–1031) vs 545 µmol/l (IQR 339–1110) P = 0.4. In this, the largest retrospective series to date, we did not detect a statistically significant difference in outcome, as determined by serum creatinine, between those patients who received corticosteroid therapy and those who did not, at 1, 6 and 12 months following presentation.
Conclusion. The results of this study do not support the routine administration of corticosteroid therapy in the management of AIN.
Comments